Ethypharm

Saint-cloud, France Founded: 1977 • Age: 49 yrs Acquired By PAI Partners
Therapies for pain and addiction treatment are developed.

About Ethypharm

Ethypharm is a Healthcare company based in Saint-cloud (France) founded in 1977, and was acquired by PAI Partners in May 2016. Therapies for pain and addiction treatment are developed. Ethypharm has raised $248.09 million across 5 funding rounds from investors including Goldman Sachs, J P Morgan and Biovail. Ethypharm has completed 2 acquisitions, including DB Ashbourne and Martindale Pharma. Its chief executive, as recorded, is Bertrand Deluard. Ethypharm offers products and services including CNS Medicines and Hospital Injectables. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Ethypharm Group.

Company details

Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.

  • Headquarters Saint-cloud, France
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website ethypharm.com
  • Social LinkedIn X
  • Acquired by PAI Partners (May 2016)
  • Legal Name Ethypharm Group
Key Metrics
  • Annual Revenue
    $167.87 M (USD)
    -4
    as on Dec 31, 2016
  • Net Profit
    $23.52 M (USD)
    85
    as on Dec 31, 2016
  • Total Equity Funding
    $248.09M (USD)

    in 5 rounds

  • Latest Funding Round
    $557.3K (USD), Grant

    Dec 2023

  • Investors
  • Investments & Acquisitions
  • Acquired by
    PAI Partners

    (May 2016)

Products & Services of Ethypharm

Ethypharm offers a comprehensive portfolio of products and services, including CNS Medicines and Hospital Injectables.

CNS Medicines
Pharmaceuticals

Treatments for severe pain and addiction disorders

Hospital Injectables
Injectable Drugs

Medications for critical care situations

Funding Insights of Ethypharm

Ethypharm has successfully raised a total of $248.09M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $557.3 thousand completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $248.09M
  • Total Rounds 5
  • Last Round Grant — $557,299
  • First Round $65M

    (Apr 2002)

  • Investors Count 5

All 5 funding rounds of Ethypharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2023$557,299Grant––
Apr 2021$952,080Grant––
Sep 2015$331.67MDebt – Conventional––
Apr 2007$183.09MSeries D–Astorg Partners
–
Apr 2002$65MSeries C–Biovail
–
Valuation history

6 investors in total: 6 institutional.

Investors in Ethypharm

Ethypharm has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, J P Morgan and Biovail.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investment banking services are delivered across multiple financial sectors.
1869goldmansachs.comNew York, United States
Astorg is engaged in private equity investment management.
astorg.comParis, France
Private equity investments in market-leading companies across global sectors.
paipartners.com
economie.gouv.fr
Comprehensive financial services are provided to corporations and individuals.
1799jpmorgan.comNew York, United States
R&D company focused on manufacturing of drugs for multiple therapeutic areas
1983biovail.comMississauga, Canada
Premium access

Investor details for Ethypharm

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Ethypharm

130 people are tracked at Ethypharm (45 in leadership, 85 in team).

NameRoleGroup
Bertrand Deluard
CEO & PresidentLeadership
Laurence Giguel
Global Portfolio And Bd&l DirectorLeadership
Neil Peters
Head Of Marketing And DigitalLeadership
Claire Amos
Head Of Payer BusinessLeadership
Amro Kamel
Commercial Director : Sales, Marketing & BD | Middle East & North AfricaLeadership
Isabelle Cheval
Business Development And Marketing Director CDMOLeadership
Joanna Eames
Head Of Business ExcellenceLeadership
Cecile Paillous
Chief Medical & Pharmaceutical Affairs OfficerLeadership
Denis Delval
President & CEOLeadership
Guilhem Maraval
COOLeadership
Hélène Moore
General Manager, Ethypharm Digital TherapyLeadership
Roseline Joannesse
Chief Legal, Ethics & Compliance OfficerLeadership
Wayne Middleton
Head Of Supply ChainLeadership
Claire Gregg
Head Of Quality Systems And ComplianceLeadership
Séverine Sy-Cornu
Corporate Talent Management & Acquisition DirectorLeadership
Paul Concannon
Senior Vice President Commercial Operations,ukLeadership
Rafael Danner
Head Of Sales D-a-chLeadership
Xavier Lasserre
Chief Commercial Operations OfficerLeadership
Tosan Neburagho
HR Business Partner, Industrial Affairs UKLeadership
Pierre-David Kramer
Finance Director - Projects / Interim ManagementLeadership

110 more people are available in the full profile.

Premium access

Complete people profiles for Ethypharm

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Ethypharm

Ethypharm has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include DB Ashbourne and Martindale Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Membrane-based humidifiers for fuel cell systems are manufactured.
martindalepharma.co.ukWooburn Green, United Kingdom1787Jan 2017••••
Procurement platform for generic medicines is provided by DB Ashbourne.
dbashbourne.comUnited Kingdom2010Oct 2015••••
Premium access

Complete acquisition details for Ethypharm

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Ethypharm

6 dated milestones of Ethypharm across 46 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ethypharm is founded.
  2. Funding First funding round of $65.0M.
  3. Acquisition Acquires DB Ashbourne.
  4. Exit Acquired by PAI Partners.
  5. Acquisition Acquires Martindale Pharma.
  6. Funding Latest funding round, Grant, of $557K.

Web traffic of Ethypharm

The website of Ethypharm (ethypharm.com) receives about 3.5K visits a month and ranks #6,712,435 among all websites worldwide, #6,719 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.5K

    ▲ 32.2% vs previous month

  • Unique visitors
    1.2K

    per month

  • Global rank
    #6,712,435

    among all websites

  • Category rank
    #6,719

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Ethypharm. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bosnalijek.com
bosnalijek.com
100%
–
amgen.com
100%
495.4K#116,434View details
aventis.com
aventis.com
100%
–
bharatserums.com
100%
View details
wdfpharm.com
wdfpharm.com
100%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 19 similar websites and full traffic analytics for Ethypharm

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 19 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ethypharm

Premium access

Complete news archive for Ethypharm

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ethypharm

Ethypharm was founded in 1977 and raised its 1st funding round 25 years after it was founded.

Ethypharm is headquartered in Saint-cloud, France.

Bertrand Deluard is the CEO of Ethypharm, as recorded in our data.

Ethypharm is a funded company, having raised a total of $248.09M across 5 funding rounds to date. The company's 1st funding round was a Series C of $65M, raised on Apr 2002.

Annual revenue of Ethypharm is $167.87M as on Dec 31, 2016.

Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.

Ethypharm offers CNS Medicines and Hospital Injectables.

Ethypharm has made 2 acquisitions, including DB Ashbourne, and Martindale Pharma.

Ethypharm has 6 investors. Key investors include Goldman Sachs, J P Morgan, Biovail, Ministry of Economy, Finance and Industrial and Digital Sovereignty, and Astorg.

Ethypharm operates through Ethypharm Group.

Yes. Ethypharm was acquired by PAI Partners in May 2016.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available